Literature DB >> 16424198

Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.

Armelle Phalipon1, Corina Costachel, Cyrille Grandjean, Audrey Thuizat, Catherine Guerreiro, Myriam Tanguy, Farida Nato, Brigitte Vulliez-Le Normand, Frédéric Bélot, Karen Wright, Véronique Marcel-Peyre, Philippe J Sansonetti, Laurence A Mulard.   

Abstract

Protection against reinfection with noncapsulated Gram-negative bacteria, such as Shigella, an enteroinvasive bacterium responsible for bacillary dysentery, is mainly achieved by Abs specific for the O-Ag, the polysaccharide part of the LPS, the major bacterial surface Ag. The use of chemically defined glycoconjugates encompassing oligosaccharides mimicking the protective determinants carried by the O-Ag, thus expected to induce an efficient anti-LPS Ab response, has been considered an alternative to detoxified LPS-protein conjugate vaccines. The aim of this study was to identify such functional oligosaccharide mimics of the S. flexneri serotype 2a O-Ag. Using protective murine mAbs specific for S. flexneri serotype 2a and synthetic oligosaccharides designed to analyze the contribution of each sugar residue of the branched pentasaccharide repeating unit of the O-Ag, we demonstrated that the O-Ag exhibited an immunodominant serotype-specific determinant. We also showed that elongating the oligosaccharide sequence improved Ab recognition. From these antigenicity data, selected synthetic oligosaccharides were assessed for their potential to mimic the O-Ag by analyzing their immunogenicity in mice when coupled to tetanus toxoid via single point attachment. Our results demonstrated that induction of an efficient serotype 2a-specific anti-O-Ag Ab response was dependent on the length of the oligosaccharide sequence. A pentadecasaccharide representing three biological repeating units was identified as a potential candidate for further development of a chemically defined glycoconjugate vaccine against S. flexneri 2a infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424198     DOI: 10.4049/jimmunol.176.3.1686

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Shigella: a model of virulence regulation in vivo.

Authors:  Benoit Marteyn; Anastasia Gazi; Philippe Sansonetti
Journal:  Gut Microbes       Date:  2012-03-01

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 3.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

5.  Development of a lipopolysaccharide-targeted peptide mimic vaccine against Q fever.

Authors:  Ying Peng; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  J Immunol       Date:  2012-10-10       Impact factor: 5.422

Review 6.  A tale of two bacterial enteropathogens and one multivalent vaccine.

Authors:  Eileen M Barry; Myron M Levine
Journal:  Cell Microbiol       Date:  2019-07-10       Impact factor: 3.715

7.  Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Authors:  Marina L Gening; Tomás Maira-Litrán; Andrea Kropec; David Skurnik; Martha Grout; Yury E Tsvetkov; Nikolay E Nifantiev; Gerald B Pier
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

8.  Dam methylation controls O-antigen chain length in Salmonella enterica serovar enteritidis by regulating the expression of Wzz protein.

Authors:  Sebastián H Sarnacki; Cristina L Marolda; Mariángeles Noto Llana; Mónica N Giacomodonato; Miguel A Valvano; María Cristina Cerquetti
Journal:  J Bacteriol       Date:  2009-08-28       Impact factor: 3.490

9.  Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody.

Authors:  B Vulliez-Le Normand; F A Saul; A Phalipon; F Bélot; C Guerreiro; L A Mulard; G A Bentley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-10       Impact factor: 11.205

10.  Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.

Authors:  Vince Pozsgay; Joanna Kubler-Kielb; Rachel Schneerson; John B Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.